A not-for-profit government organization headquartered in Canada is currently looking for new projects in the life sciences space for an allocation round in 2013. The organization was granted investment funds through the Canadian government to promote research and advancement in the life science sector. The firm typically allocates from $1 million and into the tens of millions per project. They are looking for large-scale projects in the biotech R&D space that are developing products based on genomics.
Archive | Hot Mandates RSS feed for this section
Hot Life Science Investor Mandate 3: Government Organization Seeks Large-Scale Biotech – June 13, 2013
10 JunHot Life Science Investor Mandate 1: Family Office Seeks Service Providers for Allocation – May 30, 2013
29 MayA family office in the Central United States is currently seeking to invest in, acquire or recapitalize small- to middle-market businesses. The firm is a non-traditional private equity fund in that the managers of the fund provide all of its capital. Therefore, there are no hard fund investment periods, and they are free to hold and operate portfolio companies with a very long-term perspective if required. The firm operates on an opportunistic basis and makes allocations on a case-by-case basis. They will typically invest into the tens of millions in a potential issuer. Within the life sciences and healthcare space, the partnership seeks contract manufacturing and service provider firms; they are especially interested at this time in service providers such as CRO’s and CMO’s.
Hot Life Science Investor Mandate 2: Private Equity Investor Seeking Range of Life Science Opportunities – May 30, 2013
29 MayA private equity group that invests in the life sciences space based in the Eastern US with nearly $2 billion in AUM is currently looking for new firms for potential investments for their third fund, which targeted $650 million, and currently has $350 million in dry powder to deploy to new firms over the next year or so. The firm typically allocates $20-50 million per firm, and is currently looking for firms that are seeking growth capital. The firm is interested in medtech and biotech therapeutic and diagnostic companies. The firm is very opportunistic and will look at the full gamut of subsectors. In the biotech therapeutics and diagnostics space, the fund is most interested in firms focused on infectious diseases, cardiovascular disorders, and pediatrics. They are looking for firms that have products in phase I or II of clinical trials. The firm invests in companies based globally.
Hot Life Science Investor Mandate 3: Opportunistic Family Office Invests Generally in Life Sciences – May 30, 2013
29 MayA highly opportunistic, London-based private investor backed by a single family office LP in the life sciences space is interested in making 2-4 allocations over the coming six months. Within life sciences, the firm has no specific criteria for investment and will look at opportunities regardless of sector, indication, development phase or financing round. The firm has comfortably made allocations from seed stage financings to multi-million dollar, late-stage investments. The firm has a very long-term orientation and has the capital available to make several follow-on equity capitalizations for subsequent rounds.
Hot Life Science Investor Mandate 1: PE Group Interested in Analytical Services, CROs for Upcoming Investments – May 23, 2013
22 MayA private equity group based in the Eastern US has over $250 million in total assets under management, has raised three funds, and is currently looking for new investment opportunities in the life sciences space. While the firm has no set time frame to make an investment, they would allocate to a firm within the next 3-6 months if a compelling opportunity were identified. The group typically invests around $5-20 million per company.
Currently, they are looking for firms within the R&D services space. The firm is most interested in analytical services companies, as well as contract research organizations (CROs) that specialize in toxicology, however would consider other companies that fall within the umbrella of the biotech R&D services space as well.
This PE group executes recapitalization, growth equity, and buyout transactions. The firm is only interested in companies that are cash flow positive. With that being said, the firm is looking for firms whose EBITDA is in the $1-10 million range, and has annual revenue that does not exceed $75 million.
Hot Life Science Investor Mandate 2: Large Family Office Looking for Opportunities in Medtech Subsectors – May 23, 2013
22 MayA family office located in the Western US with around $100 million in assets is looking for a compelling opportunity for allocation within the next 6-9 months. The office invested in more than five deals in 2012, typically between $1-5 million per firm.
The foundation is most interested in medical devices, and will look at firms within the full gamut of medtech subsectors. Typically, the office allocates to firms that have at least one product on the market. They have no strict criteria in terms of a firm’s EBITDA or revenue, but require that any firm in which they invest has goals to lower the cost of healthcare.
Hot Life Science Investor Mandate 3: Generalist PE Fund Interested in CRO’s, CMO’s – May 23, 2013
22 MayA private equity fund located in the Central US with roughly $1 billion under management intends to make allocations in the tens of millions on a case-by-case basis over the first half of 2013. The firm is generalist and invests across sectors, but has a specific interest in life sciences & medical technologies. Within this space, the firm is opportunistic in almost every aspect, but does require that an issuer be EBITDA-positive. This means that a firm must have at least one product on the market generating revenue to be of interest. Though the firm has looked at and invested in therapeutics and medtech companies historically, a primary interest currently is service providers such as CROs and CMOs.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 